NorthWest Biotherapeutics Inc (NWBO)

[Lykiri]

Dr. Liau was not a proponent of utilizing DC therapy on idh mutation patients in her compassionate care cases at UCLA and would refer them to other trials, because she believed idh mutation was almost akin to something other than GBM altogether. (Ahead of her time, but the neuro-oncology world is coming ‘round to this.)

First Annual UCSF Brain Tumor Center Update Symposium.
Current Management of High-Grade Gliomas - Nancy Ann Oberheim Bush, MD, PhD

March 5, 2021

"There are some very exciting changes that are coming down the pipeline. For the WHO 5th 2021 edition (CNS Tumor Classification Scheme)
gliobastoma is only going to be used for IDH wild-type tumors there's no more IDH mutant GBM."(Nancy Ann Oberheim Bush, MD, PhD)

The First Annual UCSF Brain Tumor Center Update Symposium, held on March 5th, 2021:
Preview of the WHO 2021 CNS Tumor Classification Scheme - Arie Perry, MD